

Mesna

Essential medicine status

General description

Testicular germ cell tumour Ovarian germ cell tumour Osteosarcoma Rhabdomyosarcoma Ewing sarcoma.

INN

Mesna

ATC codes

[V03AF01](#)

Medicine type

Chemical agent

EML status history

First added in 2009 ([TRS 958](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2015 ([TRS 994](#)) for [Osteosarcoma of bone and articular cartilage of other specified sites](#)

Added in 2015 ([TRS 994](#)) for [Rhabdomyosarcoma primary site](#)

Added in 2015 ([TRS 994](#)) for [Other specified malignant neoplasms of the ovary](#)

Added in 2015 ([TRS 994](#)) for [Germ cell tumour of testis](#)

Added in 2015 ([TRS 994](#)) for [Ewing sarcoma of bone and articular cartilage of unspecified sites](#)

Removed in 2015 ([TRS 994](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2021 ([TRS 1035](#)) for [Burkitt lymphoma including Burkitt leukaemia](#)

Added in 2021 ([TRS 1035](#)) for [Malignant neoplasms of kidney, except renal pelvis](#)

Wikipedia

[Mesna](#)

DrugBank

[Mesna \(Coenzyme M\)](#)

Recommendations

Section

Supportive medicines

- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
- Oral > Solid > tablet: 400 mg; 600 mg
- Oral > Other: 600 mg
- Oral > Solid > tablet: 400 mg
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg

Indications

[Osteosarcoma of bone and articular cartilage of other specified sites](#) [Rhabdomyosarcoma primary site](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant neoplasms of kidney, except renal pelvis](#)